Pay in 4 interest-free payments of $6.14 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
This application is based on data from the SOUL cardiovascular outcomes trial that demonstrated a 14% relative risk reduction in MACE in patients treated with Rybelsus 14 mg orally once daily for approximately five years compared to those who received placebo
Barone, V
These real-world findings underscore modest benefits when combined with lifestyle changes
Business Type Manufacturer, Supplier Establishment 1998 Working Days To Related Products Explore Related Categories More Products From This Seller Seller Details Ahmedabad, Gujarat Proprietor Mr
US$ 22.59
US$ 28.42
US$ 26.47
US$ 28.56
US$ 29.74
US$ 20.24
